'Lv dysfunction' diaporamas de présentation

Timing and indications of surgery in stenotic and regurgitant valvular lesions

Timing and indications of surgery in stenotic and regurgitant valvular lesions. Dr.Deepak Raju. Aortic stenosis. Pathophysiology Assessment of severity Natural history Management strategy Role of exercise test,EBCT Recommendations. Concept of afterload mismatch.

876 views • 74 slides

HIGH TECH 2012

708 views • 51 slides

Current and planned clinical research in DMD

Newcastle Collaborative work Dr Michelle Eagle Research Practitioner Physiotherapist Newcastle Muscle Centre. Current and planned clinical research in DMD. Where do we need more evidence in DMD?. Medicine cannot be ruled by anecdote. How do we best use the drugs we have already got?

615 views • 50 slides

Viability assessment and its role in Revascularization

Viability assessment and its role in Revascularization. Review of evidence Dr. Nithin P G. Overview. Introduction Viability assessment by various investigations Comparisons Clinical correlations Benefits of viability assessment in clinical scenario Conclusion. Introduction. TERMS

650 views • 49 slides

The Electrical Management of Cardiac Rhythm Disorders Tachycardia Indications for ICD Implantation

The Electrical Management of Cardiac Rhythm Disorders Tachycardia Indications for ICD Implantation. Guidelines. ACC/AHA/ESC 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and Prevention of Sudden Cardiac Death Full document is 100 pages Executive summary is 44 pages

656 views • 48 slides

702 views • 48 slides

650 views • 47 slides

CARDIAC TOXICITY OF CANCER THERAPEUTIC AGENTS

CARDIAC TOXICITY OF CANCER THERAPEUTIC AGENTS. Dr Binjo J Vazhappilly Senior Resident. New anticancer therapies have led to long life expectancy for many patients. Treatment related co morbidities have become an issue for cancer survivors.

605 views • 45 slides

Cardiac Resynchronization Therapy (CRT)

Cardiac Resynchronization Therapy (CRT). Vineeta Ahooja MD FACC Advanced Imaging, Cardiovascular Medicine Heart Health Institute. Vineeta Ahooja MD FACC Wayne State University 2000-2006 Internal Medicine and Cardiovascular Medicine

1.3k views • 44 slides

The Treatment of Advanced Heart Failure

The Treatment of Advanced Heart Failure. Shiva Roy FRACP POWH Nov 2000. Heart Failure: where are we now?. CCF is a major health problem 400,000 new cases / yr in USA 300,000 Australians affected Care is expensive 70% of costs relate to hospitalisation

827 views • 43 slides

Tehran Heart Center Tehran University of Medical Sciences

PCI VS CABG. M . SALARIFAR , MD. Tehran Heart Center Tehran University of Medical Sciences. PCI VS CABG. From 1987 to 2003 326% increase in PCI Now more than 90% stenting. PCI VS CABG. Factors in patient selection.

798 views • 40 slides

A Case of Life-Threatening Hypertensive Crisis during Hepatic Radiofrequency Ablation

669 views • 38 slides

MEDPHARM DRUGS FOR ISCHEMIC HEART DISEASE

FEBRUARY 10,2110. MEDPHARM DRUGS FOR ISCHEMIC HEART DISEASE. VIGNETTE. A 47 yr old man reports a 6 month Hx of chest pressure while playing handball.He describes substernal tightness and left arm numbness only while exerting.The total cholesterol and LDL are elevated. The

491 views • 34 slides

Practical Considerations in Chronic Ischemic Heart Disease Management

Practical Considerations in Chronic Ischemic Heart Disease Management. Angina treatment: Objectives. Reduce ischemia and relieve anginal symptoms Improve quality of life Prevent MI and death Improve quantity of life.

856 views • 28 slides

Cosa ci possono dire la genetica e la biopsia miocardica

Centro di Riferimento Cardiomiopatie Azienda Osp. Universitaria Careggi. Cosa ci possono dire la genetica e la biopsia miocardica. Iacopo Olivotto Dipartimento Cuore e Vasi Azienda Ospedaliero-Universitaria Careggi Firenze 31 Ottobre 2008. Desmin. Dystrophin.

389 views • 23 slides

386 views • 20 slides

Jay H Traverse, MD Principal Investigator, LateTIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital Un

The LateTIME Randomized Trial : Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2-3 Weeks following AMI. Jay H Traverse, MD Principal Investigator, LateTIME Study

303 views • 15 slides

Primary Arterial Switch beyond 3 Weeks of age : What is feasible without ECLS?

Primary Arterial Switch beyond 3 Weeks of age : What is feasible without ECLS?. Krishna Iyer, Girish Kumar, Reetesh Gupta, Sunil Kaushal, Sameer Girotra, S. Radhakrishnan, Parvathi Iyer, Savitri Shrivastava Escorts Heart Institute & Research Centre, New Delhi, INDIA.

123 views • 1 slides

Chronic Ischemic MR with LV dysfunction

Chronic Ischemic MR with LV dysfunction. Modification of EROA (cm2). Target. Dobutamine. Tool. Improve Function (presence of viability). Peripheral Effects ( afterload). Effects. Reduction of Mitral Orifice. Results. EROA.

154 views • 1 slides

Primary Arterial Switch beyond 3 Weeks of age : What is feasible without ECLS?

Primary Arterial Switch beyond 3 Weeks of age : What is feasible without ECLS?. Krishna Iyer, Girish Kumar, Reetesh Gupta, Sunil Kaushal, Sameer Girotra, S. Radhakrishnan, Parvathi Iyer, Savitri Shrivastava Escorts Heart Institute & Research Centre, New Delhi, INDIA.

108 views • 1 slides